Recent Updates
Recently added Catalysts
SIBN Positive Sentiment

SI-BONE To Present at Truist Securities 2024 MedTech Conference on June 18, 2024

Key Takeaway: SI-BONE, Inc. announced its participation in the 2024 Truist Securities MedTech Conference in Boston, set for June 18, 2024. The company will conduct a fireside chat to discuss its pioneering technology in treating musculoskeletal disorders. SI-BONE has a proven history in minimally invasive surgery, having supported over 3,700 surgeons and carried out over 100,000 procedures. The conference provides an opportunity for investors to understand the company's innovations and performance.
Price reaction · baseline $13.75 (2024-06-04 close) · hit after-hours · clean, no other SIBN news in the window
day 0 close · peak
+2.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • SI-BONE will introduce its innovations at a prominent MedTech conference.
  • The company has a strong track record with over 100,000 sacropelvic procedures.
  • Management is engaging with investors through a live webcast.

Full Press Release Details

SANTA CLARA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2024 Truist Securities MedTech Conference in Boston. Management will be hosting a fireside chat on Tuesday, June 18, at 3:40 p.m. Eastern Time / 12:40 p.m. Pacific Time.
Investors interested in listening to the conference call may do so by registering at this link: https://wsw.com/webcast/truist5/sibn/2067200. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since pioneering minimally invasive surgery of the SI joint in 2009, SI-BONE has supported over 3,700 surgeons in performing a total of more than 100,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including four randomized controlled trials and over 130 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation, and pelvic trauma.
For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

Frequently Asked Questions

When will SI-BONE participate in the Truist Securities MedTech Conference?

SI-BONE will participate on June 18, 2024, at 3:40 p.m. Eastern Time.

How can I listen to the SI-BONE conference call?

Investors can register to listen at the provided webcast link.

Where can I find the archived webcast of the conference?

The webcast will be archived on the SI-BONE website for at least 90 days.

What is SI-BONE’s specialty in medical technology?

SI-BONE specializes in minimally invasive surgery for musculoskeletal disorders.

How many sacropelvic procedures has SI-BONE supported?

SI-BONE has supported over 100,000 sacropelvic procedures to date.

Last updated: Jun 5, 2024